Christoph Becker1, Kilian Konrad Kenjiro Dahlem2, Kitty Lange2, Manuel Christoph Ketterer2, Jens Pfeiffer2. 1. University Medical Centre Freiburg, Department of Otorhinolaryngology - Head and Neck Surgery, Freiburg, Germany. Electronic address: christoph.becker@uniklinik-freiburg.de. 2. University Medical Centre Freiburg, Department of Otorhinolaryngology - Head and Neck Surgery, Freiburg, Germany.
Abstract
INTRODUCTION: To evaluate the influence of comorbidities and anemia on outcome and survival in patients with sinonasal carcinomas. MATERIALS AND METHODS: Review of medical records of 121 patients with carcinoma treated at a single quaternary medical care and cancer center between 2002 and 2015. Comorbidities were classified according to the age-adjusted Charlson comorbidity index (ACCI) scoring system. RESULTS: 71 patients were male, 50 were female. Median age was 65 years, and the median interval between tumor diagnosis and date of study inclusion was 71 months. The most common histological subtype was squamous cell carcinoma (n = 64). The median ACCI score was 2 and the most frequent ACCI score was 0 (n = 26). Mean overall survival was 52.2 months (ACCI 0-2) and 39.5 months (ACCI ≥ 3), respectively (p < 0.0001). Mean disease-free survival was 52.9 months (ACCI 0-2) and 45.5 months (ACCI ≥ 3), respectively (p = 0.026). Mean overall survival in patients without anemia was 49.5 months, compared with 39.8 months in patients with anemia (p = 0.043). CONCLUSION: Comorbidity is an independent risk factor on overall, disease-free and disease-specific survival in patients with sinonasal carcinoma. Anemia is associated with shorter overall survival. This is the first study evaluating comorbidity using the ACCI scoring system and focusing on patients with sinonasal carcinoma.
INTRODUCTION: To evaluate the influence of comorbidities and anemia on outcome and survival in patients with sinonasal carcinomas. MATERIALS AND METHODS: Review of medical records of 121 patients with carcinoma treated at a single quaternary medical care and cancer center between 2002 and 2015. Comorbidities were classified according to the age-adjusted Charlson comorbidity index (ACCI) scoring system. RESULTS: 71 patients were male, 50 were female. Median age was 65 years, and the median interval between tumor diagnosis and date of study inclusion was 71 months. The most common histological subtype was squamous cell carcinoma (n = 64). The median ACCI score was 2 and the most frequent ACCI score was 0 (n = 26). Mean overall survival was 52.2 months (ACCI 0-2) and 39.5 months (ACCI ≥ 3), respectively (p < 0.0001). Mean disease-free survival was 52.9 months (ACCI 0-2) and 45.5 months (ACCI ≥ 3), respectively (p = 0.026). Mean overall survival in patients without anemia was 49.5 months, compared with 39.8 months in patients with anemia (p = 0.043). CONCLUSION: Comorbidity is an independent risk factor on overall, disease-free and disease-specific survival in patients with sinonasal carcinoma. Anemia is associated with shorter overall survival. This is the first study evaluating comorbidity using the ACCI scoring system and focusing on patients with sinonasal carcinoma.
Authors: M C Ketterer; L A Lemus Moraga; U Beitinger; J Pfeiffer; A Knopf; C Becker Journal: Eur Arch Otorhinolaryngol Date: 2020-02-11 Impact factor: 2.503